1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Proteon Therapeutics

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2001

Location

Waltham MA US

Primary Industry

Biotechnology

Established

2001

Firm Ownership

-

Investment Team Staff

Total Staff

-

Request a demo to show more

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin
31 Dec 2014
2,948,000
-
(7,580,000)
(257.1%)
(7,520,000)
(255.1%)
(3,342,000)
(113.4%)
31 Dec 2015
0
(100%)
(20,870,000)
-
(20,162,000)
-
(21,377,000)
-
31 Dec 2016
0
-
(28,705,000)
-
(28,451,000)
-
(28,526,000)
-
31 Dec 2017
0
-
(30,362,000)
-
(30,216,000)
-
(29,964,000)
-
31 Dec 2018
0
-
(21,372,000)
-
(21,308,000)
-
(20,729,000)
-
31 Dec 2019
-
-
(15,254,000)
-
(14,979,000)
-
(14,992,000)
-
31 Dec 2020
-
-
(34,444,000)
-
(34,248,000)
-
(33,978,000)
-
31 Dec 2021
31 Dec 2022
31 Dec 2023

Unlock the recent years of financials and more for Proteon Therapeutics.

Request a demo to see more.

Key Contacts

Name Position Start Date End Date Vcard Bio
Board of Directors BM
BM Board Member
Name Firm Deal Date Number Of Deals Vcard
AI LP
AI LP
AI Active Investor LP Lead Provider

Want to see more?

Request a demo for full access to this profile.

Employee Data

Employee Graph

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.